Update on the diagnosis and management of thalassemia

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 1, 2014, Pages 56-59

  Weiss, Mitchell J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; GLOBIN; HYDROXYUREA;

ALPHA THALASSEMIA; ANEMIA; ARTICLE; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CHROMATOGRAPHY; CLINICAL TRIAL (TOPIC); DYSERYTHROPOIESIS; GENE DELETION; GENE MUTATION; GENE THERAPY; GENETIC SCREENING; GLOBIN GENE; HUMAN; IRON DEFICIENCY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLOR; THALASSEMIA; THALASSEMIA INTERMEDIA; WEIGHT GAIN; BLOOD; BLOOD TRANSFUSION; GENETICS; INTERVIEW;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; GENETIC THERAPY; HUMANS; THALASSEMIA;

EID: 84893013276     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467(7313):318-322.
2. Clinicaltrials. gov. A study evaluating the safety and efficacy of the LentiGlobin® BB305 drug product in beta-thalassemia major subjects. http://clinicaltrials.gov/show/NCT01745120. Identifier: NCT01745120. Accessed November 20, 2013.
3. Nienhuis AW, Persons DA. Development of gene therapy for thalassemia. Cold Spring Harb Perspect Med. 2012;2(11). http://perspectivesinmedicine.cshlp.org/content/2/11/a011833.full.pdf+html. Published November 2012. Accessed December 8, 2013.
4. Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977;297(8):418-423.
5. Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med. 1976;294(26):1421-1423.
6. Sankaran VG. Targeted therapeutic strategies for fetal hemoglobin induction. Hematology Am Soc Hematol Educ Program. 2011;2011(1):459-465. http://asheducationbook.hematologylibrary.org/content/2011/1/459.full.pdf+html?sid=0cd7a46d-f987-480c-b450-85063e8fe3ac. Published December 2011. Accessed December 8, 2013.
7. Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V; Thalassaemia International Federation. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). http://www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Non-Transfusion%20Dependent%20Thalassaemias%20(2013)/NTDT%20ENGLISH.pdf. Accessed December 8, 2013.
8. Weatherall DJ, Schechter AN, Nathan DG, eds. Hemoglobin and Its Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013. http://perspectivesinmedicine.cshlp.org/site/misc/hemoglobin_and_its_diseases.xhtml. Accessed December 8, 2013.
9. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312(25):1600-1603.